Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry

Authors

  • Raye Z. Litten,

    Corresponding author
    1. National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) (RZL, MR, DF, JF), Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    • Reprint requests: Raye Z. Litten, PhD, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane, Bethesda, MD 20892-9304; Tel.: 301-443-0636; Fax: 301-480-5790; E-mail: rlitten@mail.nih.gov

    Search for more papers by this author
  • Megan Ryan,

    1. National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) (RZL, MR, DF, JF), Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Search for more papers by this author
  • Daniel Falk,

    1. National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) (RZL, MR, DF, JF), Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Search for more papers by this author
  • Joanne Fertig

    1. National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) (RZL, MR, DF, JF), Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Search for more papers by this author

Abstract

The process of developing pharmacological treatments for alcohol use disorder is notoriously complex and challenging. The path to market is long, costly, and inefficient. One way of expediting and reducing the drug development process is through collaborations—building partnerships among government, academia, pharmaceutical and biotechnology companies, healthcare organizations and advocacy groups, and the patients (end consumers) themselves. By forging collaborations, particularly with pharmaceutical companies, the alcohol treatment field stands to reap benefits in generating new medications for use in mainstream treatment settings. At the same time, there are certain caveats that should be considered, particularly by academic researchers, before entering into such partnerships. This commentary examines the advantages and caveats of government and academia collaborations with pharmaceutical companies.

Ancillary